

CITATION REPORT

List of articles citing

**Systematic review and meta-analysis:
levofloxacin-based rescue regimens after *Helicobacter pylori* treatment failure**

DOI: 10.1111/j.1365-2036.2006.02737.x

Alimentary Pharmacology and Therapeutics, 2006, 23, 35-44.

Source: <https://exaly.com/paper-pdf/40425691/citation-report.pdf>

Version: 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
292	Helicobacter pylori therapy: what is coming?. 2006 , 16, 1107-1112		4
291	[A case of nonresected gastric cancer with peritoneal dissemination maintained on TS-1, cisplatin (CDDP) and docetaxel combination chemotherapy with good QOL]. <i>Therapy: Open Access in Clinical Medicine</i> , 2006 , 33, 251-3		24
290	Peptic ulcer disease. 2006 , 22, 607-11		4
289	Bibliography. Current world literature. Stomach and duodenum. 2006 , 22, 680-9		
288	Randomized comparison of two rescue therapies for Helicobacter pylori infection. 2006 , 36, 803-9		29
287	Levofloxacin-based rescue regimens after Helicobacter pylori treatment failure: how strong is the evidence?. <i>Alimentary Pharmacology and Therapeutics</i> , 2006 , 23, 1283-5; author reply 1285-6	6.1	3
286	Levofloxacin-based rescue regimens after Helicobacter pylori treatment failure: how strong is the evidence? Author's reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2006 , 23, 1285-1286	6.1	1
285	Third-line rescue therapy with levofloxacin is more effective than rifabutin rescue regimen after two Helicobacter pylori treatment failures. <i>Alimentary Pharmacology and Therapeutics</i> , 2006 , 24, 1469-74	6.1	62
284	Treatment of Helicobacter pylori infection. <i>Helicobacter</i> , 2006 , 11 Suppl 1, 36-9	4.9	33
283	Prevalence and mechanisms of resistance to fluoroquinolones in Helicobacter pylori strains from patients living in Belgium. <i>Helicobacter</i> , 2006 , 11, 441-5	4.9	72
282	Strategien der Helicobacter-pylori-Eradikation. 2006 , 1, 266-271		1
281	[Recommendations for the management of Helicobacter pylori infection according to Maastricht 3 guidelines]. 2006 , 30, 1361-4		5
280	'Rescue' therapies for the management of Helicobacter pylori infection. 2006 , 24, 113-30		41
279	The treatment of Helicobacter pylori infection: the changing picture of a still unresolved problem. 2006 , 15, 991-4		
278	Alpha-fetoprotein and hepatocellular carcinoma. <i>American Journal of Gastroenterology</i> , 2006 , 101, 1939; author reply 1940-1	0.7	13
277	Triple levofloxacin-based rescue therapy is an accepted empirical third-line treatment. <i>American Journal of Gastroenterology</i> , 2006 , 101, 1938; author reply 1938-9	0.7	5
276	Alpha Fetoprotein in Hepatocellular Carcinoma: Reply to Letter to Editor. <i>American Journal of Gastroenterology</i> , 2006 , 101, 1940-1941	0.7	1

275	Levofloxacin-Based Regimens: An Alternative for Second- and Third-Line Eradication Treatment After H. pylori Eradication Failures: Reply to Dr. Rokkas and Gisbert. <i>American Journal of Gastroenterology</i> , 2006 , 101, 1938-1939	0.7	1
274	Effective regimens for the treatment of Helicobacter pylori infection. 2006 , 15, 995-1016		15
273	Subject Index To Volume 1. 2007 , 2, 3-7		
272	Recent Advances in the Treatment of Helicobacter pylori Infection. 2007 , 2, 197-205		3
271	American College of Gastroenterology guideline on the management of Helicobacter pylori infection. <i>American Journal of Gastroenterology</i> , 2007 , 102, 1808-25	0.7	957
270	Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. <i>Gut</i> , 2007 , 56, 772-81	19.2	1326
269	The sequential therapy regimen for Helicobacter pylori eradication: a pooled-data analysis. <i>Gut</i> , 2007 , 56, 1353-7	19.2	210
268	Treatment strategy to eradicate Helicobacter pylori infection: impact of pharmacogenomics-based acid inhibition regimen and alternative antibiotics. 2007 , 8, 2701-17		25
267	Treatment and dosing of Helicobacter pylori infection: when pharmacology meets clinic. 2007 , 8, 329-50		17
266	Eradication therapy for Helicobacter pylori. <i>Gastroenterology</i> , 2007 , 133, 985-1001	13.3	179
265	"Cervia II Working Group Report 2006": guidelines on diagnosis and treatment of Helicobacter pylori infection in Italy. <i>Digestive and Liver Disease</i> , 2007 , 39, 782-9	3.3	81
264	Helicobacter pylori eradication with either quadruple regimen with lactoferrin or levofloxacin-based triple therapy: a multicentre study. <i>Digestive and Liver Disease</i> , 2007 , 39, 806-10	3.3	25
263	Levofloxacin-based triple therapy for Helicobacter pylori re-treatment: role of bacterial resistance. <i>Digestive and Liver Disease</i> , 2007 , 39, 1001-5	3.3	77
262	Treatment of Helicobacter pylori. 2007 , 21, 315-24		59
261	Primary antibiotic resistance in Helicobacter pylori strains isolated in northern and central Italy. <i>Alimentary Pharmacology and Therapeutics</i> , 2007 , 25, 1429-34	6.1	91
260	First-line triple therapy with levofloxacin for Helicobacter pylori eradication. <i>Alimentary Pharmacology and Therapeutics</i> , 2007 , 26, 495-500	6.1	44
259	Clinical trial: levofloxacin-based quadruple therapy was inferior to traditional quadruple therapy in the treatment of resistant Helicobacter pylori infection. <i>Alimentary Pharmacology and Therapeutics</i> , 2007 , 26, 1063-7	6.1	22
258	The effectiveness of rifabutin triple therapy for patients with difficult-to-eradicate Helicobacter pylori in clinical practice. <i>Alimentary Pharmacology and Therapeutics</i> , 2007 , 26, 1537-42	6.1	46

257	Empirical rescue therapy after <i>Helicobacter pylori</i> treatment failure: a 10-year single-centre study of 500 patients. <i>Alimentary Pharmacology and Therapeutics</i> , 2008 , 27, 346-54	6.1	64
256	Levofloxacin- vs. ranitidine bismuth citrate-containing therapy after <i>H. pylori</i> treatment failure. <i>Helicobacter</i> , 2007 , 12, 68-73	4.9	18
255	Levofloxacin in first-line treatment of <i>Helicobacter pylori</i> infection. <i>Helicobacter</i> , 2007 , 12, 364-5	4.9	20
254	Treatment of <i>Helicobacter pylori</i> . <i>Helicobacter</i> , 2007 , 12 Suppl 1, 31-7	4.9	82
253	Second-line treatment for <i>Helicobacter pylori</i> infection: 10-day moxifloxacin-based triple therapy versus 2-week quadruple therapy. <i>Helicobacter</i> , 2007 , 12, 623-8	4.9	38
252	Evolution of <i>Helicobacter pylori</i> therapy from a meta-analytical perspective. <i>Helicobacter</i> , 2007 , 12 Suppl 2, 50-8	4.9	60
251	What is new in the management of <i>Helicobacter pylori</i> ?. 2008 , 177, 185-8		9
250	One-week once-daily triple therapy with esomeprazole, moxifloxacin, and rifabutin for eradication of persistent <i>Helicobacter pylori</i> resistant to both metronidazole and clarithromycin. <i>Helicobacter</i> , 2008 , 13, 69-74	4.9	51
249	Treatment of <i>Helicobacter pylori</i> infection. <i>Helicobacter</i> , 2008 , 13 Suppl 1, 35-40	4.9	95
248	Failure of <i>Helicobacter pylori</i> treatment after regimes containing clarithromycin: new practical therapeutic options. <i>Helicobacter</i> , 2008 , 13, 572-6	4.9	30
247	Third Chinese National Consensus Report on the management of <i>Helicobacter pylori</i> infection. 2008 , 9, 178-84		22
246	[Acid-related diseases. What is the current rescue treatment of choice for <i>Helicobacter pylori</i> : quadruple therapy (proton pump inhibitor, bismuth, tetracycline and metronidazole) or triple therapy with proton pump inhibitor, amoxicillin and levofloxacin?]. <i>Gastroenterologĭa Y Hepatologĭa</i> , 2008 , 31, 100-4	0.9	1
245	[Acid-related diseases. How long should eradication therapy last when a proton pump inhibitor and 2 antibiotics are used: 7, 10 or 14 days?]. <i>Gastroenterologĭa Y Hepatologĭa</i> , 2008 , 31, 468-9	0.9	
244	[<i>Helicobacter pylori</i> -related diseases: dyspepsia, ulcer and gastric cancer]. <i>Gastroenterologĭa Y Hepatologĭa</i> , 2008 , 31 Suppl 4, 18-28	0.9	2
243	Sequential therapy for <i>Helicobacter pylori</i> : time to consider making the switch?. 2008 , 300, 1346-7		22
242	Emerging therapies for the treatment of <i>Helicobacter pylori</i> infections. 2008 , 42, 1621-39		18
241	An alternative salvage regimen for <i>Helicobacter pylori</i> -resistant patients with heart failure. 2008 , 110, 112-5		3
240	Second-line rescue therapy with levofloxacin after <i>H. pylori</i> treatment failure: a Spanish multicenter study of 300 patients. <i>American Journal of Gastroenterology</i> , 2008 , 103, 71-6	0.7	65

239	Failure of first-line eradication treatment significantly increases prevalence of antimicrobial-resistant <i>Helicobacter pylori</i> clinical isolates. 2008 , 61, 1112-5		50
238	Prise en charge diagnostique et th�rapeutique de l'infection \square <i>Helicobacter pylori</i> . 2008 , 3, 1-7		1
237	Treatment of <i>Helicobacter pylori</i> infection. 2008 , 337, a1454		29
236	Quinolone-Based Third-Line Therapy for <i>Helicobacter pylori</i> Eradication. 2009 , 44, 119-24		43
235	S3-guideline "helicobacter pylori and gastroduodenal ulcer disease" of the German society for digestive and metabolic diseases (DGVS) in cooperation with the German society for hygiene and microbiology, society for pediatric gastroenterology and nutrition e. V., German society for rheumatology, AWMF-registration-no. 021 / 001. 2009 , 47, 1230-63		48
234	[S3-guideline " <i>Helicobacter pylori</i> and gastroduodenal ulcer disease"]. 2009 , 47, 68-102		56
233	Sitafloxacin activity against <i>Helicobacter pylori</i> isolates, including those with gyrA mutations. 2009 , 53, 3097-9		34
232	Is furazolidone therapy for <i>Helicobacter pylori</i> effective and safe?. 2009 , 54, 2298-9		5
231	[<i>Helicobacter pylori</i>]. 2009 , 50, 979-86; quiz 987		4
230	Virulence factor genotypes of <i>Helicobacter pylori</i> affect cure rates of eradication therapy. 2009 , 57, 45-56		48
229	Resistance to metronidazole, clarithromycin and levofloxacin of <i>Helicobacter pylori</i> before and after clarithromycin-based therapy in Taiwan. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2009 , 24, 1230-5	4	60
228	<i>Helicobacter pylori</i> : antibiotic resistance and treatment options. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2009 , 24, 1155-7	4	15
227	Second Asia-Pacific Consensus Guidelines for <i>Helicobacter pylori</i> infection. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2009 , 24, 1587-600	4	415
226	Moxifloxacin-containing triple therapy as second-line treatment for <i>Helicobacter pylori</i> infection: effect of treatment duration and antibiotic resistance on the eradication rate. <i>Helicobacter</i> , 2009 , 14, 77-85	4-9	43
225	Peptic ulcer disease. 2009 , 374, 1449-61		532
224	Second-line levofloxacin-based triple schemes for <i>Helicobacter pylori</i> eradication. <i>Digestive and Liver Disease</i> , 2009 , 41, 480-5	3-3	47
223	H. pylori treatment: new wine in old bottles?. <i>American Journal of Gastroenterology</i> , 2009 , 104, 26-30	0-7	44
222	Systematic reviews: the good, the bad, and the ugly. <i>American Journal of Gastroenterology</i> , 2009 , 104, 1086-92	0-7	68

221	Second-line rescue therapy of helicobacter pylori infection. 2009 , 2, 331-56		17
220	Levofloxacin, Amoxicillin, and Omeprazole as first-line triple therapy for Helicobacter pylori eradication. 2009 , 43, 384-5		17
219	PEG placement causing liver perforation. 2009 , 43, 385		2
218	Helicobacter pylori: diagnosis and treatment. 2009 , 25, 549-56		28
217	In Response:. 2010 , 44, 658-659		26
216	Sequential therapy for Helicobacter pylori eradication: a critical review. 2010 , 44, 313-25		159
215	Guidelines for the management of Helicobacter pylori infection in Japan: 2009 revised edition. <i>Helicobacter</i> , 2010 , 15, 1-20	4-9	355
214	Ten-day sequential therapy as first-line treatment for Helicobacter pylori infection in Korea: a retrospective study. <i>Helicobacter</i> , 2010 , 15, 148-53	4-9	36
213	Sequential metronidazole-furazolidone or clarithromycin-furazolidone compared to clarithromycin-based quadruple regimens for the eradication of Helicobacter pylori in peptic ulcer disease: a double-blind randomized controlled trial. <i>Helicobacter</i> , 2010 , 15, 497-504	4-9	23
212	Is short-term therapy really sufficient to eradicate Helicobacter pylori infection?. 2010 , 11, 690-701		2
211	[Modern Helicobacter pylori therapies in times of increasing anti biotic resistance]. 2010 , 105, 787-91		
210	Advantages of Moxifloxacin and Levofloxacin-based triple therapy for second-line treatments of persistent Helicobacter pylori infection: a meta analysis. 2010 , 122, 413-22		47
209	Bismuth salts in the treatment of Helicobacter pylori infection in children. 2010 , 55, 535-6		1
208	Criterios actuales para la erradicaci3n de Helicobacter pylori. 2010 , 17, 158-166		
207	Efficacy and tolerability of first-line triple therapy with levofloxacin and amoxicillin plus esomeprazole or rabeprazole for the eradication of Helicobacter pylori infection and the effect of CYP2C19 genotype: a 1-week, randomized, open-label study in Chinese adults. 2010 , 32, 2003-11		26
206	Efficacy of 1-week proton pump inhibitor triple therapy as first-line Helicobacter pylori eradication regime in Asian patients: is it still effective 10 years on?. 2010 , 11, 244-8		17
205	Rescue therapy using a rifabutin-based regimen is effective for cure of Helicobacter pylori infection. 2010 , 24, 303-6		18
204	CYP2C19 genotypes in the pharmacokinetics/pharmacodynamics of proton pump inhibitor-based therapy of Helicobacter pylori infection. 2010 , 6, 29-41		37

203	The sequential therapy regimen for <i>Helicobacter pylori</i> eradication. 2010 , 11, 905-18		12
202	Donn�es actuelles sur la prise en charge de l'infection par <i>Helicobacter pylori</i> . 2010 , 12, 137-144		2
201	Clinical practice. <i>Helicobacter pylori</i> infection. 2010 , 362, 1597-604		528
200	<i>Helicobacter pylori</i> eradication therapy. 2010 , 5, 639-48		78
199	Ulcer Disease and <i>Helicobacter pylori</i> Infection: Etiology and Treatment. 2010 , 102-138		1
198	<i>Helicobacter pylori</i> first-line treatment and rescue option containing levofloxacin in patients allergic to penicillin. <i>Digestive and Liver Disease</i> , 2010 , 42, 287-90	3.3	43
197	Efficacy of <i>H. pylori</i> eradication with a sequential regimen followed by rescue therapy in clinical practice. <i>Digestive and Liver Disease</i> , 2010 , 42, 541-3	3.3	29
196	Efficacy and safety of Levofloxacin, Clarithromycin and Esomeprazol as first line triple therapy for <i>Helicobacter pylori</i> eradication in Middle East. Prospective, randomized, blind, comparative, multicenter study. 2010 , 21, 310-4		24
195	Treatment of <i>Helicobacter pylori</i> infection: the past and the future. 2010 , 21, 357-9		26
194	Levofloxacin-based and clarithromycin-based triple therapies as first-line and second-line treatments for <i>Helicobacter pylori</i> infection: a randomised comparative trial with crossover design. <i>Gut</i> , 2010 , 59, 572-8	19.2	84
193	Optimal management of peptic ulcer disease in the elderly. 2010 , 27, 545-58		36
192	[Rescue therapy after <i>Helicobacter pylori</i> eradication failure]. <i>Gastroenterology Y Hepatology</i> , 2011 , 34, 89-99	0.9	15
191	[<i>Helicobacter pylori</i> -related diseases: dyspepsia, ulcers and gastric cancer]. <i>Gastroenterology Y Hepatology</i> , 2011 , 34 Suppl 2, 15-26	0.9	3
190	[Regional difference of antibiotic resistance of <i>helicobacter pylori</i> strains in Korea]. 2011 , 57, 221-9		36
189	[Primary antibiotic resistance of <i>Helicobacter pylori</i> strains and eradication rate according to gastroduodenal disease in Korea]. 2011 , 58, 74-81		23
188	Evidence-based guidelines from ESPGHAN and NASPGHAN for <i>Helicobacter pylori</i> infection in children. 2011 , 53, 230-43		199
187	Triple therapy with ecabet sodium, amoxicillin and lansoprazole for 2 weeks as the rescue regimen for <i>H. pylori</i> infection. 2011 , 50, 369-74		12
186	Review article: non-bismuth quadruple (concomitant) therapy for eradication of <i>Helicobacter pylori</i> . <i>Alimentary Pharmacology and Therapeutics</i> , 2011 , 34, 604-17	6.1	116

185	Analysis of antibiotic susceptibility patterns of <i>Helicobacter pylori</i> isolates from Malaysia. <i>Helicobacter</i> , 2011 , 16, 47-51	4.9	24
184	Moxifloxacin-containing triple therapy versus bismuth-containing quadruple therapy for second-line treatment of <i>Helicobacter pylori</i> infection: a meta-analysis. <i>Helicobacter</i> , 2011 , 16, 131-8	4.9	29
183	Quadruple therapy with medications containing either rufloxacin or furazolidone as a rescue regimen in the treatment of <i>Helicobacter pylori</i> -infected dyspepsia patients: a randomized pilot study. <i>Helicobacter</i> , 2011 , 16, 284-8	4.9	14
182	Randomized trial on 14 versus 7 days of esomeprazole, moxifloxacin, and amoxicillin for second-line or rescue treatment of <i>Helicobacter pylori</i> infection. <i>Helicobacter</i> , 2011 , 16, 420-6	4.9	38
181	Enfermedades relacionadas con <i>Helicobacter pylori</i> : dispepsia, úlcera y cáncer gástrico. <i>Gastroenterología Y Hepatología</i> , 2011 , 34, 16-27	0.9	4
180	[Current value of quinolones in <i>Helicobacter pylori</i> therapy]. 2011 , 49, 989-96		2
179	A clinician's guide to salvage therapy for persistent <i>Helicobacter pylori</i> infection. 2011 , 39, 133-40		4
178	Genotypic resistance in <i>Helicobacter pylori</i> strains correlates with susceptibility test and treatment outcomes after levofloxacin- and clarithromycin-based therapies. 2011 , 55, 1123-9		55
177	Empirical modified sequential therapy containing levofloxacin and high-dose esomeprazole in second-line therapy for <i>Helicobacter pylori</i> infection: a multicentre clinical trial. 2011 , 66, 1847-52		40
176	Treatment of <i>Helicobacter pylori</i> . 2011 , 27, 565-70		44
175	A randomized study comparing levofloxacin, omeprazole, nitazoxanide, and doxycycline versus triple therapy for the eradication of <i>Helicobacter pylori</i> . <i>American Journal of Gastroenterology</i> , 2011 , 106, 1970-5	0.7	72
174	Should quinolones come first in <i>Helicobacter pylori</i> therapy?. 2011 , 4, 103-14		47
173	Empiric therapies for <i>Helicobacter pylori</i> infections. 2011 , 183, E506-8		13
172	Efficacy of sitafloxacin-based rescue therapy for <i>Helicobacter pylori</i> after failures of first- and second-line therapies. 2012 , 56, 1643-5		45
171	[Diagnosis of <i>Helicobacter pylori</i> infection]. 2012 , 101, 787-92		
170	Rescue Therapy for <i>Helicobacter pylori</i> Infection 2012. <i>Gastroenterology Research and Practice</i> , 2012 , 2012, 974594	2	31
169	Salvage Options for Eradication of <i>Helicobacter pylori</i> During Tetracycline Backorder. 2012 , 28, 187-192		1
168	Efficacy of a therapeutic strategy for eradication of <i>Helicobacter pylori</i> infection. <i>World Journal of Gastroenterology</i> , 2012 , 18, 4542-8	5.6	6

167	Infecci3 por <i>Helicobacter pylori</i> . <i>Medicine</i> , 2012 , 11, 90-96		0.1	
166	Levofloxacin versus clarithromycin in a 10 day triple therapy regimen for first-line <i>Helicobacter pylori</i> eradication: a single-blind randomized clinical trial. 2012 , 67, 2254-9			14
165	High-dose rabeprazole-amoxicillin dual therapy and rabeprazole triple therapy with amoxicillin and levofloxacin for 2 weeks as first and second line rescue therapies for <i>Helicobacter pylori</i> treatment failures. <i>Alimentary Pharmacology and Therapeutics</i> , 2012 , 35, 1097-102	6.1		22
164	A modified bismuth-containing quadruple therapy including a short course of furazolidone for <i>Helicobacter pylori</i> eradication after sequential therapy failure. <i>Helicobacter</i> , 2012 , 17, 264-8	4.9		19
163	The efficacy of second-line anti- <i>Helicobacter pylori</i> therapy using an extended 14-day levofloxacin/amoxicillin/proton-pump inhibitor treatment--a pilot study. <i>Helicobacter</i> , 2012 , 17, 374-81	4.9		56
162	Gemifloxacin can partially overcome quinolone resistance of <i>H. pylori</i> with <i>gyrA</i> mutation in Taiwan. <i>Helicobacter</i> , 2012 , 17, 210-5	4.9		22
161	<i>Helicobacter pylori</i> infection: sequential therapy followed by levofloxacin-containing triple therapy provides a good cumulative eradication rate. <i>Helicobacter</i> , 2012 , 17, 246-53	4.9		26
160	Therapeutic management of recurrent peptic ulcer disease. 2012 , 72, 1605-16			11
159	Sitafloxacin resistance in <i>Helicobacter pylori</i> isolates and sitafloxacin-based triple therapy as a third-line regimen in Japan. 2012 , 39, 352-5			26
158	[Clinical practice guideline on the management of patients with dyspepsia. Update 2012]. 2012 , 44, 727.e1-727.e38			
157	Different Antibiotic No Culture Eradicating (DANCE) strategy: an easy way to manage <i>H. pylori</i> eradication. <i>Digestive and Liver Disease</i> , 2012 , 44, 889-92	3.3		9
156	[Clinical practice guideline on the management of patients with dyspepsia. Update 2012]. <i>Gastroenterolog3 Y Hepatolog3</i> , 2012 , 35, 725.e1-38	0.9		7
155	Diagnosis of <i>Helicobacter pylori</i> infection. 2012 , 344, e828			18
154	Primary resistance of <i>Helicobacter pylori</i> to levofloxacin and moxifloxacin in Iran. 2012 , 7, 447-52			29
153	[<i>Helicobacter pylori</i> -related diseases]. <i>Gastroenterolog3 Y Hepatolog3</i> , 2012 , 35 Suppl 1, 12-25	0.9		5
152	Management of <i>Helicobacter pylori</i> infection--the Maastricht IV/ Florence Consensus Report. <i>Gut</i> , 2012 , 61, 646-64	19.2		1615
151	Update on non-bismuth quadruple (concomitant) therapy for eradication of <i>Helicobacter pylori</i> . <i>Clinical and Experimental Gastroenterology</i> , 2012 , 5, 23-34	3.1		98
150	Treatment prospects of <i>Helicobacter pylori</i> infection. 2012 , 2, 70-77			1

149	Update on triple therapy for eradication of <i>Helicobacter pylori</i> : current status of the art. <i>Clinical and Experimental Gastroenterology</i> , 2012 , 5, 151-7	3.1	23
148	<i>Helicobacter pylori</i> persistence in children: distinguishing inadequate treatment, resistant organisms, and reinfection. 2012 , 14, 236-42		9
147	Randomised clinical trial: a comparative study of 10-day sequential therapy with 7-day standard triple therapy for <i>Helicobacter pylori</i> infection in naïve patients. <i>Alimentary Pharmacology and Therapeutics</i> , 2012 , 35, 56-65	6.1	65
146	Review article: rifabutin in the treatment of refractory <i>Helicobacter pylori</i> infection. <i>Alimentary Pharmacology and Therapeutics</i> , 2012 , 35, 209-21	6.1	132
145	Fourth-line rescue therapy with rifabutin in patients with three <i>Helicobacter pylori</i> eradication failures. <i>Alimentary Pharmacology and Therapeutics</i> , 2012 , 35, 941-7	6.1	50
144	Letter: third-line rescue therapy with levofloxacin after failure of two treatments to eradicate <i>Helicobacter pylori</i> infection. Author's reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2012 , 35, 1486-1486	6.1	3
143	Safety and efficacy of 1-week levofloxacin-based triple therapy in first-line treatment for <i>Helicobacter pylori</i> -related peptic ulcer disease in Kashmir, India. 2013 , 32, 32-6		3
142	Cumulative <i>Helicobacter pylori</i> eradication therapy in obese patients undergoing gastric bypass surgery. 2013 , 23, 145-9		12
141	[<i>Helicobacter pylori</i> -related diseases]. <i>Gastroenterología Y Hepatología</i> , 2013 , 36 Suppl 2, 39-50	0.9	3
140	Efficacy of two levofloxacin-containing second-line therapies for <i>Helicobacter pylori</i> : a pilot study. <i>Helicobacter</i> , 2013 , 18, 378-83	4.9	12
139	Comparison of 10 day bismuth quadruple therapy with high-dose metronidazole or levofloxacin for second-line <i>Helicobacter pylori</i> therapy: a randomized controlled trial. 2013 , 68, 222-8		41
138	Effect of fluoroquinolone resistance on 14-day levofloxacin triple and triple plus bismuth quadruple therapy. <i>Helicobacter</i> , 2013 , 18, 373-7	4.9	72
137	[III Spanish Consensus Conference on <i>Helicobacter pylori</i> infection]. <i>Gastroenterología Y Hepatología</i> , 2013 , 36, 340-74	0.9	49
136	A review of rescue regimens after clarithromycin-containing triple therapy failure (for <i>Helicobacter pylori</i> eradication). 2013 , 14, 843-61		62
135	Clinical evaluation of a ten-day regimen with esomeprazole, metronidazole, amoxicillin, and clarithromycin for the eradication of <i>Helicobacter pylori</i> in a high clarithromycin resistance area. <i>Helicobacter</i> , 2013 , 18, 459-67	4.9	50
134	Current options for the treatment of <i>Helicobacter pylori</i> . 2013 , 14, 211-23		40
133	Sequential therapy versus standard triple-drug therapy for <i>Helicobacter pylori</i> eradication: a prospective randomized study. 2013 , 69, 1709-15		22
132	Second-line rescue triple therapy with levofloxacin after failure of non-bismuth quadruple "sequential" or "concomitant" treatment to eradicate <i>H. pylori</i> infection. 2013 , 48, 652-6		25

131	Helicobacter pylori: tailored therapy with novel sequential quadruple therapies. 2013 , 10, 6-8		5
130	Ten-Day versus 14-Day Levofloxacin-Containing Triple Therapy for Second-Line Anti-Helicobacter pylori Eradication in Taiwan. <i>Gastroenterology Research and Practice</i> , 2013 , 2013, 932478	2	14
129	Second-line therapy with levofloxacin after failure of treatment to eradicate helicobacter pylori infection: time trends in a Spanish Multicenter Study of 1000 patients. 2013 , 47, 130-5		51
128	The incidence of primary antibiotic resistance of Helicobacter pylori in Vietnam. 2013 , 47, 233-8		44
127	3rd Brazilian Consensus on Helicobacter pylori. 2013 , 50,		23
126	A review of Helicobacter pylori diagnosis, treatment, and methods to detect eradication. <i>World Journal of Gastroenterology</i> , 2014 , 20, 1438-49	5.6	118
125	Primary Helicobacter pylori Eradication Rates of Lansoprazole, Amoxicillin, and Metronidazole Therapy is Much Higher than Lansoprazole, Amoxicillin and Clarithromycin Therapy in Chiba Prefecture, Japan. 2014 , 04,		
124	Evidence-based assessment of proton-pump inhibitors in Helicobacter pylori eradication: a systematic review. <i>World Journal of Gastroenterology</i> , 2014 , 20, 14527-36	5.6	8
123	The evolution of Helicobacter pylori antibiotics resistance over 10 years in Greece. 2014 , 90, 229-31		26
122	Ideal treatment for Helicobacter pylori: A systematic review. 2014 , 79, 28-49		1
121	[Ideal treatment for Helicobacter pylori: a systematic review]. 2014 , 79, 28-49		8
120	Levofloxacin and proton pump inhibitor-based triple therapy versus standard triple first-line therapy for Helicobacter pylori eradication. 2014 , 23, 443-55		12
119	New dual therapy for primary treatment of Helicobacter pylori infection: A prospective randomized study in Shanghai, China. 2014 , 15, 622-7		20
118	Practical treatment of Helicobacter pylori: a balanced view in changing times. <i>European Journal of Gastroenterology and Hepatology</i> , 2014 , 26, 819-25	2.2	18
117	Clinical management of Helicobacter pylori: the Latin American perspective. 2014 , 32, 302-9		9
116	Second and third line treatment options for Helicobacter pylori eradication. <i>World Journal of Gastroenterology</i> , 2014 , 20, 1517-28	5.6	29
115	Quinolone-containing therapies in the eradication of Helicobacter pylori. 2014 , 2014, 151543		8
114	Third-line rescue therapy with bismuth-containing quadruple regimen after failure of two treatments (with clarithromycin and levofloxacin) for H. pylori infection. 2014 , 59, 383-9		37

113	Eradication of <i>Helicobacter pylori</i> infection. 2014 , 30, 167-72		16
112	Is levofloxacin-based triple therapy an alternative for first-line eradication of <i>Helicobacter pylori</i> ? A systematic review and meta-analysis. 2014 , 49, 528-38		25
111	[Diseases linked to <i>Helicobacter pylori</i> infection]. <i>Gastroenterología Y Hepatología</i> , 2014 , 37 Suppl 3, 40-52	0.9	1
110	Pretreatment antimicrobial susceptibility-guided vs. clarithromycin-based triple therapy for <i>Helicobacter pylori</i> eradication in a region with high rates of multiple drug resistance. <i>American Journal of Gastroenterology</i> , 2014 , 109, 1595-602	0.7	53
109	Treatment of <i>Helicobacter pylori</i> infection: Past, present and future. 2014 , 5, 392-9		50
108	Optimum antibiotic doses for <i>Helicobacter pylori</i> eradication. <i>The Cochrane Library</i> , 2014 ,	5.2	
107	Quinolones. 2015 , 419-439.e8		6
106	Eradication rates for <i>Helicobacter pylori</i> infection a systematic evidence - based review. 2015 , 87, 377-386		
105	Antibiotic Resistance of <i>Helicobacter pylori</i> Among Male United States Veterans. 2015 , 13, 1616-24		101
104	Two-week, high-dose proton pump inhibitor, moxifloxacin triple <i>Helicobacter pylori</i> therapy after failure of standard triple or non-bismuth quadruple treatments. <i>Digestive and Liver Disease</i> , 2015 , 47, 108-13	3.3	18
103	Comparison of efficacy and safety of levofloxacin-containing versus standard sequential therapy in eradication of <i>Helicobacter pylori</i> infection in Korea. <i>Digestive and Liver Disease</i> , 2015 , 47, 114-8	3.3	16
102	<i>Helicobacter pylori</i> first-line and rescue treatments in the presence of penicillin allergy. 2015 , 60, 458-64		36
101	Beyond Maastricht IV: are standard empiric triple therapies for <i>Helicobacter pylori</i> still useful in a South-European country?. <i>BMC Gastroenterology</i> , 2015 , 15, 23	3	7
100	Practical Aspects in Choosing a <i>Helicobacter pylori</i> Therapy. 2015 , 44, 519-35		10
99	<i>Helicobacter pylori</i> second-line rescue therapy with levofloxacin- and bismuth-containing quadruple therapy, after failure of standard triple or non-bismuth quadruple treatments. <i>Alimentary Pharmacology and Therapeutics</i> , 2015 , 41, 768-75	6.1	72
98	Prevalence of Primary Resistance of <i>Helicobacter pylori</i> to Clarithromycin and Levofloxacin in Southern Spain. 2015 , 92, 78-82		24
97	Effect of bacterial and host factors on <i>Helicobacter pylori</i> eradication therapy. 2015 , 19, 1637-50		13
96	Fourteen-day optimized levofloxacin-based therapy versus classical quadruple therapy for <i>Helicobacter pylori</i> treatment failures: a randomized clinical trial. 2015 , 50, 1185-90		30

95	High-dose dual therapy is superior to standard first-line or rescue therapy for <i>Helicobacter pylori</i> infection. 2015 , 13, 895-905.e5		103
94	Eradication Rate by Duration of Third-line Rescue Therapy with Levofloxacin after <i>Helicobacter pylori</i> Treatment Failure in Clinical Practice. 2016 , 68, 260-264		9
93	Infectious Aetiology of Marginal Zone Lymphoma and Role of Anti-Infective Therapy. 2016 , 8, e2016006		21
92	A Randomized Control Trial Comparing 2 Levofloxacin-Containing Second-Line Therapies for <i>Helicobacter pylori</i> Eradication. <i>Medicine (United States)</i> , 2016 , 95, e3586	1.8	17
91	Efficacy of 10-day Sifloxacin-Containing Third-Line Rescue Therapies for <i>Helicobacter pylori</i> Strains Containing the <i>gyrA</i> Mutation. <i>Helicobacter</i> , 2016 , 21, 286-94	4.9	29
90	IV Spanish Consensus Conference on <i>Helicobacter pylori</i> infection treatment. <i>Gastroenterología Y Hepatología (English Edition)</i> , 2016 , 39, 697-721	0.1	4
89	UEG Week 2016 Poster Presentations. <i>United European Gastroenterology Journal</i> , 2016 , 4, A157-A720	5.3	12
88	<i>Helicobacter pylori</i> -related diseases. <i>Gastroenterología Y Hepatología</i> , 2016 , 39 Suppl 1, 36-46	0.9	3
87	<i>Helicobacter pylori</i> Therapy. 2016 , 471-490		
86	<i>Helicobacter pylori</i> therapy: a paradigm shift. <i>Expert Review of Anti-Infective Therapy</i> , 2016 , 14, 577-85	5.5	61
85	The Toronto Consensus for the Treatment of <i>Helicobacter pylori</i> Infection in Adults. <i>Gastroenterology</i> , 2016 , 151, 51-69.e14	13.3	443
84	<i>Helicobacter pylori</i> Research. 2016 ,		3
83	IV Spanish Consensus Conference on <i>Helicobacter pylori</i> infection treatment. <i>Gastroenterología Y Hepatología</i> , 2016 , 39, 697-721	0.9	80
82	Treatment of <i>Helicobacter pylori</i> infection: Where are we now?. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016 , 31, 1918-1926	4	21
81	Pharmacological regimens for eradication of <i>Helicobacter pylori</i> : an overview of systematic reviews and network meta-analysis. <i>BMC Gastroenterology</i> , 2016 , 16, 80	3	20
80	High efficacy of gemifloxacin-containing therapy in <i>Helicobacter Pylori</i> eradication: A pilot empirical second-line rescue therapy. <i>Medicine (United States)</i> , 2016 , 95, e4410	1.8	10
79	<i>Helicobacter pylori</i> . 2016 ,		3
78	Levofloxacin, bismuth, amoxicillin and esomeprazole as second-line <i>Helicobacter pylori</i> therapy after failure of non-bismuth quadruple therapy. <i>Digestive and Liver Disease</i> , 2016 , 48, 506-511	3.3	18

77	Paciente con infección por <i>Helicobacter pylori</i> resistente al tratamiento. <i>Medicine</i> , 2016 , 12, 110.e1-110.e5.1		
76	Levofloxacin or Clarithromycin-based quadruple regimens: what is the best alternative as first-line treatment for <i>Helicobacter pylori</i> eradication in a country with high resistance rates for both antibiotics?. <i>BMC Gastroenterology</i> , 2017 , 17, 31	3	8
75	Proton pump inhibitor- and fluoroquinolone-based triple therapies for <i>Helicobacter pylori</i> eradication. <i>The Cochrane Library</i> , 2017 ,	5.2	0
74	Optimization strategies aimed to increase the efficacy of <i>H. pylori</i> eradication therapies. <i>Helicobacter</i> , 2017 , 22, e12392	4.9	40
73	The Irish <i>Helicobacter pylori</i> Working Group consensus for the diagnosis and treatment of <i>H. pylori</i> infection in adult patients in Ireland. <i>European Journal of Gastroenterology and Hepatology</i> , 2017 , 29, 552-559	2.2	23
72	A prospective evaluation of levofloxacin-based triple therapy for refractory <i>Helicobacter pylori</i> infection in Australia. <i>Internal Medicine Journal</i> , 2017 , 47, 761-766	1.6	8
71	Management of <i>Helicobacter pylori</i> infection-the Maastricht V/Florence Consensus Report. <i>Gut</i> , 2017 , 66, 6-30	19.2	1488
70	Illusions regarding clinical trials and treatment guidelines. <i>Gut</i> , 2017 , 66, 2043-2046	19.2	20
69	Comparison of <i>Helicobacter pylori</i> Eradication Rates of 2-Week Levofloxacin-Containing Triple Therapy, Levofloxacin-Containing Bismuth Quadruple Therapy, and Standard Bismuth Quadruple Therapy as a First-Line Regimen. <i>Medical Principles and Practice</i> , 2017 , 26, 523-529	2.1	8
68	Efficacy and Safety of the Triple Therapy Containing Ilaprazole, Levofloxacin, and Amoxicillin as First-Line Treatment in Infections. <i>Gastroenterology Research and Practice</i> , 2017 , 2017, 1654907	2	6
67	The first-line regimens of <i>Helicobacter pylori</i> eradication in Korea. <i>Hanyang Medical Reviews</i> , 2017 , 37, 2		1
66	Systematic review, meta-analysis, and meta-regression: Successful second-line treatment for <i>Helicobacter pylori</i> . <i>Helicobacter</i> , 2018 , 23, e12488	4.9	12
65	Molecular characterization of <i>Helicobacter pylori</i> resistance to rifamycins. <i>Helicobacter</i> , 2018 , 23, e12451.9	4.9	20
64	An electrochemical sensor based on poly (l-Cysteine)@AuNPs @ reduced graphene oxide nanocomposite for determination of levofloxacin. <i>Microchemical Journal</i> , 2019 , 147, 198-206	4.8	38
63	<i>Helicobacter pylori</i> Infection. 2019 ,		
62	Systematic review and network meta-analysis: Comparative effectiveness of therapies for second-line <i>Helicobacter pylori</i> eradication. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019 , 34, 59-67	4	16
61	Rescue therapy with rifabutin regimen for refractory <i>Helicobacter pylori</i> infection with dual drug-resistant strains. <i>BMC Gastroenterology</i> , 2020 , 20, 218	3	5
60	High Antibiotic Resistance of and Its Associated Novel Gene Mutations among the Mongolian Population. <i>Microorganisms</i> , 2020 , 8,	4.9	9

59	Optimization Strategies Aimed to Increase the Efficacy of Eradication Therapies with Quinolones. <i>Molecules</i> , 2020 , 25,	4.8	3
58	Green-synthesized Cu ₂ O nanoaggregates incorporated on Cyclodextrin for catalytic reduction and electrochemical sensing. <i>Journal of the Iranian Chemical Society</i> , 2020 , 17, 2613-2626	2	5
57	Potential of selected lactic acid bacteria from Theobroma cacao fermented fruit juice and cell-free supernatants from cultures as inhibitors of Helicobacter pylori and as good probiotic. <i>BMC Research Notes</i> , 2020 , 13, 64	2.3	5
56	Reevaluation of the Efficacy of First Line Regimen for. <i>Clinical and Experimental Gastroenterology</i> , 2020 , 13, 25-33	3.1	4
55	Salvage Regimens after Failure of Previous Helicobacter pylori Eradication Therapy: A Systematic Review and Meta-analysis. <i>The Korean Journal of Helicobacter and Upper Gastrointestinal Research</i> , 2021 , 21, 59-71	0.4	0
54	Evidence-Based Guidelines for the Treatment of Infection in Korea 2020. <i>Gut and Liver</i> , 2021 , 15, 168-195	4.8	15
53	Adverse Event Profile During the Treatment of Helicobacter pylori: A Real-World Experience of 22,000 Patients From the European Registry on H. pylori Management (Hp-EuReg). <i>American Journal of Gastroenterology</i> , 2021 , 116, 1220-1229	0.7	15
52	Evidence based guidelines for the treatment of Helicobacter pylori infection in Korea 2020. <i>Korean Journal of Internal Medicine</i> , 2021 , 36, 807-838	2.5	1
51	Evidence-Based Guidelines for the Treatment of Helicobacter pylori Infection in Korea: 2020 Revised Edition. <i>Korean Journal of Medicine</i> , 2021 , 96, 160-189	0.5	
50	Levofloxacin or Rifabutin-Based Triple Therapy. 2016 , 473-478		1
49	Quinolones. 2010 , 487-510		6
48	Levofloxacin-based first-line therapy versus standard first-line therapy for Helicobacter pylori eradication: meta-analysis of randomized controlled trials. <i>PLoS ONE</i> , 2014 , 9, e85620	3.7	18
47	The clinical and bacteriological factors for optimal levofloxacin-containing triple therapy in second-line Helicobacter pylori eradication. <i>PLoS ONE</i> , 2014 , 9, e105822	3.7	24
46	treatment in Turkey: Current status and rational treatment options. <i>İstanbul Kuzey Klinikleri</i> , 2020 , 7, 87-94	0.8	4
45	Second-line treatment for Helicobacter pylori eradication after sequential therapy failure: a pilot study. <i>Therapy: Open Access in Clinical Medicine</i> , 2006 , 3, 251-254		1
44	[New opportunities for the prevention of gastric cancer]. <i>Terapevticheskii Arkhiv</i> , 2017 , 89, 101-109	0.9	6
43	Helicobacter pylori and gastroduodenal ulcer disease. <i>Deutsches A&#x0308;rzteblatt International</i> , 2009 , 106, 801-8	2.5	14
42	Rifabutin for the Treatment of Infection: A Review. <i>Pathogens</i> , 2020 , 10,	4.5	11

41	"Rescue" regimens after Helicobacter pylori treatment failure. <i>World Journal of Gastroenterology</i> , 2008 , 14, 5385-402	5.6	82
40	A new look at anti-Helicobacter pylori therapy. <i>World Journal of Gastroenterology</i> , 2011 , 17, 3971-5	5.6	113
39	Levofloxacin/amoxicillin-based schemes vs quadruple therapy for Helicobacter pylori eradication in second-line. <i>World Journal of Gastroenterology</i> , 2012 , 18, 5669-78	5.6	39
38	Antibiotics resistance rate of Helicobacter pylori in Bhutan. <i>World Journal of Gastroenterology</i> , 2013 , 19, 5508-12	5.6	14
37	Helicobacter pylori: management in 2013. <i>World Journal of Gastroenterology</i> , 2014 , 20, 5302-7	5.6	8
36	Helicobacter pylori eradication with moxifloxacin-containing therapy following failed first-line therapies in South Korea. <i>World Journal of Gastroenterology</i> , 2014 , 20, 6932-8	5.6	17
35	Fluoroquinolone-based protocols for eradication of Helicobacter pylori. <i>World Journal of Gastroenterology</i> , 2014 , 20, 8947-56	5.6	3
34	Treatment of Helicobacter pylori infection: meeting the challenge of antimicrobial resistance. <i>World Journal of Gastroenterology</i> , 2014 , 20, 9898-911	5.6	68
33	Management of Helicobacter pylori infection in Latin America: a Delphi technique-based consensus. <i>World Journal of Gastroenterology</i> , 2014 , 20, 10969-83	5.6	17
32	Efficacy of 14-d vs 7-d moxifloxacin-based triple regimens for second-line Helicobacter pylori eradication. <i>World Journal of Gastroenterology</i> , 2015 , 21, 5568-74	5.6	6
31	Moxifloxacin-containing triple therapy after non-bismuth quadruple therapy failure for Helicobacter pylori infection. <i>World Journal of Gastroenterology</i> , 2015 , 21, 13124-31	5.6	9
30	Update on quinolone-containing rescue therapies for infection. <i>World Journal of Gastroenterology</i> , 2020 , 26, 1733-1744	5.6	4
29	Diagnosis and Treatment of Helicobacter Pylori Infection. <i>Korean Journal of Medicine</i> , 2015 , 89, 149-156	0.5	2
28	Levofloxacin, Metronidazole, and Lansoprazole Triple Therapy Compared to Quadruple Therapy as a Second-Line Treatment of Helicobacter pylori Infection in Korea. <i>Gut and Liver</i> , 2013 , 7, 406-10	4.8	18
27	The efficacy of moxifloxacin-containing triple therapy after standard triple, sequential, or concomitant therapy failure for Helicobacter pylori eradication in Korea. <i>Gut and Liver</i> , 2014 , 8, 605-11	4.8	11
26	High Efficacy of Levofloxacin-Dexlansoprazole-Based Quadruple Therapy as a First Line Treatment for Helicobacter pylori Eradication in Thailand. <i>Asian Pacific Journal of Cancer Prevention</i> , 2015 , 16, 4353-6	1.7	11
25	Evidence-based Guidelines for the Treatment of Helicobacter pylori Infection in Korea: 2020 Revised Edition. <i>The Korean Journal of Helicobacter and Upper Gastrointestinal Research</i> , 2020 , 20, 261-287	0.4	7
24	Therapeutic Potential of Sitafloxacin as a New Drug Candidate for Eradication in Korea: An In Vitro Culture-Based Study. <i>Antibiotics</i> , 2021 , 10,	4.9	0

23	V Spanish Consensus Conference on Helicobacter pylori infection treatment. <i>Gastroenterología Y Hepatología (English Edition)</i> , 2021 ,	0.1	
22	V Spanish Consensus Conference on Helicobacter pylori infection treatment. <i>Gastroenterología Y Hepatología</i> , 2021 ,	0.9	3
21	Helicobacter pylori. 2008 , 900-907		
20	Treatment of Helicobacter pylori. <i>The Korean Journal of Helicobacter and Upper Gastrointestinal Research</i> , 2011 , 11, 21	0.4	
19	The Optimal Second-line Rescue Therapy after Failure of Non-bismuth Quadruple Treatments. <i>The Korean Journal of Helicobacter and Upper Gastrointestinal Research</i> , 2015 , 15, 145	0.4	
18	Ten Years Retrospective Study about Helicobacter pylori Eradication Rate. <i>The Korean Journal of Helicobacter and Upper Gastrointestinal Research</i> , 2015 , 15, 112	0.4	
17	The Comparison of Levofloxacin- and Clarithromycin-Based Bismuth Quadruple Therapy Regimens in Eradication. <i>Journal of Research in Pharmacy Practice</i> , 2020 , 9, 101-105	1.3	1
16	Advances in the treatment of infection in children. <i>Annals of Gastroenterology</i> , 2015 , 28, 10-18	2.2	9
15	Efficacy of Clarithromycin Containing Bismuth-Based Regimen as a Second-Line Therapy in Helicobacter Pylori Eradication. <i>Middle East Journal of Digestive Diseases</i> , 2015 , 7, 75-81	1.1	5
14	Comparison of levofloxacin versus clarithromycin efficacy in the eradication of Helicobacter pylori infection. <i>Caspian Journal of Internal Medicine</i> , 2016 , 7, 267-271	1	5
13	Effectiveness of 7-Day and 14-Day Moxifloxacin-Dexlansoprazole Based Triple Therapy and Probiotic Supplement for Helicobacter Pylori Eradication in Thai Patients with Non-Ulcer Dyspepsia: A Double-Blind Randomized Placebo-Controlled Study. <i>Asian Pacific Journal of Cancer Prevention</i> , 2017 , 18, 2839-2843	1.7	2
12	Efficacy of levofloxacin, omeprazole, nitazoxanide, and doxycycline (LOAD) regimen compared with standard triple therapy to eradicate infection: a prospective randomized study from a tertiary hospital in India. <i>Gastroenterology and Hepatology From Bed To Bench</i> , 2021 , 14, 342-348	1.2	0
11	Levofloxacin-based therapy as an efficient alternative for eradicating Helicobacter pylori infection in Iran: a systematic review and meta-analysis. <i>Journal of Global Antimicrobial Resistance</i> , 2021 ,	3.4	2
10	Next-Generation Sequencing-Based Study of Isolates from Myanmar and Their Susceptibility to Antibiotics.. <i>Microorganisms</i> , 2022 , 10,	4.9	4
9	Experience with Rifabutin-Containing Therapy in 500 Patients from the European Registry on Management (Hp-EuReg).. <i>Journal of Clinical Medicine</i> , 2022 , 11,	5.1	2
8	Levofloxacin versus clarithromycin for Helicobacter pylori eradication: are 14' day regimens better than 10' day regimens?. <i>Gut Pathogens</i> , 2022 , 14,	5.4	0
7	Practice guidelines for the management of Helicobacter pylori infection: The Saudi H. pylori Working Group recommendations. 2022 , 0		0
6	Evaluation of the Antibiotic Resistance Rate of Helicobacter pylori in Peptic Ulcer Patients in Tien Giang Central General Hospital, Tien Giang Province, Vietnam. 2022 , 10, 1835-1839		0

- 5 Antibiotic Resistance of *Helicobacter pylori* in Patients with Peptic Ulcer. **2023**, 59, 6 ○
- 4 Third-line and rescue therapy for refractory *Helicobacter pylori* infection: A systematic review. 29, 390-409 ○
- 3 MAT Gain of Activity Mutation in *Helicobacter pylori* Is Associated with Resistance to MTAN Transition State Analogues. **2023**, 9, 966-978 ○
- 2 Characteristics of phenotypic antibiotic resistance of *Helicobacter pylori* and its correlation with genotypic antibiotic resistance: A retrospective study in Ningxia. ○
- 1 Levofloxacin+Tetracycline Quadruple Regimen for Eradication of *Helicobacter pylori*: A Multicenter Multinational Randomized Controlled Trial. **2023**, 15, 12-18 ○